| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $42,745,595 ) (Continued on the next page) |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K23DK131368 | Improving Transition Care for Adolescents and Young Adults with Type 1 Diabetes: A Randomized Controlled Trial of SHIFT2 | 000 | 5 | NIH | 5/22/2026 | $138,323 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | H7600555 | EARLY INTERVENTION SERVICES | 01 | 27 | HRSA | 5/11/2026 | $489,088 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | H7600555 | EARLY INTERVENTION SERVICES | 00 | 27 | HRSA | 3/30/2026 | $97,816 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R25HL161607 | Undergraduate Cardiovascular Research Program | 000 | 5 | NIH | 5/4/2026 | $123,120 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01CA290863 | Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC) | 001 | 2 | NIH | 4/13/2026 | $0 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01CA290863 | Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC) | 002 | 2 | NIH | 4/16/2026 | $64,040 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01CA290863 | Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC) | 000 | 2 | NIH | 4/2/2026 | $576,356 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01DA030005 | Genetic, Social, and Developmental Epidemiology of Drug Use Disorders | 000 | 15 | NIH | 6/1/2026 | $1 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01DK135815 | Modeling genetic contributions to biliary atresia | 000 | 4 | NIH | 5/4/2026 | $588,673 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | U01AG076481 | Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease | 001 | 5 | NIH | 6/5/2026 | $1,513,190 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R35GM155045 | Dissecting mechanisms of collective migration | 000 | 3 | NIH | 6/5/2026 | $366,579 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01CA285692 | MYCN drives a druggable SUMOylation program in neuroblastoma | 001 | 3 | NIH | 4/16/2026 | $42,520 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01CA285692 | MYCN drives a druggable SUMOylation program in neuroblastoma | 000 | 3 | NIH | 12/15/2025 | $382,682 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R37CA269249 | Regulatory T cell modulation of reactive astrogliosis in brain metastasis | 000 | 5 | NIH | 5/26/2026 | $430,968 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R35HL155651 | Managing Cardiac Toxicities of Cancer Therapy | 001 | 6 | NIH | 4/23/2026 | $23,286 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R35HL155651 | Managing Cardiac Toxicities of Cancer Therapy | 000 | 6 | NIH | 3/9/2026 | $737,439 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K12AR084233 | Building Interdisciplinary Research Careers in Women's Health | 001 | 6 | NIH | 6/1/2026 | $451,328 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K12AR084233 | Building Interdisciplinary Research Careers in Women's Health | 001 | 6 | NIH | 6/1/2026 | $90,000 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K12AR084233 | Building Interdisciplinary Research Careers in Women's Health | 001 | 6 | NIH | 6/1/2026 | $100,000 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K12AR084233 | Building Interdisciplinary Research Careers in Women's Health | 001 | 6 | NIH | 6/1/2026 | $1 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R34DA058494 | Development and testing of cognitive behavioral therapy for insomnia adapted for patients in opioid use disorder treatment | 000 | 3 | NIH | 3/31/2026 | $271,688 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K01DA060994 | Hippocampal memory mechanisms in nicotine relapse | 001 | 3 | NIH | 5/19/2026 | $163,117 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01DA060724 | Opioid and non-opioid receptor mechanisms in neurons and glia underlying fentanyl and HIV comorbidity in the striatum | 000 | 3 | NIH | 3/24/2026 | $661,789 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | U01DA051037 | 20/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT VCU | 000 | 7 | NIH | 4/9/2026 | $1,456,225 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | U24NS100673 | SIREN CORE-EM HUB ALLIANCE | 002 | 9 | NIH | 2/26/2026 | $15,338 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | U24NS100673 | SIREN CORE-EM HUB ALLIANCE | 002 | 9 | NIH | 2/26/2026 | $15,317 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | U24NS100673 | SIREN CORE-EM HUB ALLIANCE | 000 | 9 | NIH | 1/29/2026 | $138,040 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | U24NS100673 | SIREN CORE-EM HUB ALLIANCE | 000 | 9 | NIH | 1/29/2026 | $137,858 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | T32TR004362 | CTSA Predoctoral T32 at Virginia Commonwealth University | 001 | 3 | NIH | 4/13/2026 | $2,488 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | T32TR004362 | CTSA Predoctoral T32 at Virginia Commonwealth University | 000 | 3 | NIH | 12/24/2025 | $228,135 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | T2554977 | Addiction Medicine Fellowship | 00 | 2 | HRSA | 5/27/2026 | $454,137 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R61AI179996 | Development of genetic tools for Orientia tsutsugamushi | 000 | 3 | NIH | 1/2/2026 | $266,917 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R35GM152058 | Ins and outs of the bioactive sphingolipid metabolite sphingosine-1-phosphate | 001 | 3 | NIH | 3/17/2026 | $38,812 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R35GM152058 | Ins and outs of the bioactive sphingolipid metabolite sphingosine-1-phosphate | 000 | 3 | NIH | 12/12/2025 | $349,313 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01HL163101 | Protein S-Palmitoylation in the Heart: Function and Regulation in Health and Disease | 001 | 4 | NIH | 4/22/2026 | $12,433 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01HL163101 | Protein S-Palmitoylation in the Heart: Function and Regulation in Health and Disease | 000 | 4 | NIH | 3/19/2026 | $393,790 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K12CA300624 | The Massey/VCU’s McCaskill-Stevens K12 for Community Oncology and Prevention Research | 000 | 1 | NIH | 4/24/2026 | $54,000 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R21CA296691 | Explore a novel therapeutic approach in advanced prostate cancer | 000 | 1 | NIH | 5/7/2026 | $399,187 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R21CA308922 | Utilizing Glycosaminoglycans as a Theragnostic Approach for Treating Platinum-Resistant Gynecological Malignancies | 000 | 1 | NIH | 5/11/2026 | $399,187 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01AG093992 | Selective Vulnerability of Cholinergic Neurons in Alzheimer’s Disease | 000 | 1 | NIH | 12/26/2025 | $552,883 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | K99AI199056 | Orientia tsutsugamsuhi promotes interplay between circadian rhythm and hypoxic responses | 000 | 1 | NIH | 5/11/2026 | $138,861 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01AG076912 | Probing neuroinflammation in Alzheimer's disease with NLRP3 PET radiotracers | 000 | 2 | NIH | 3/24/2026 | $625,387 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | F31DE035007 | Exploration of the role of FOSL1-mediated liquid-liquid phase separation in cisplatin resistance in HNSCC | 001 | 1 | NIH | 4/16/2026 | $576 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | F31DE035007 | Exploration of the role of FOSL1-mediated liquid-liquid phase separation in cisplatin resistance in HNSCC | 000 | 1 | NIH | 2/4/2026 | $44,691 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | F31DA065413 | Site and outcomes of lynx1 allosteric modulation of α3β4-nicotinic receptors with relevance to nicotine use disorder | 001 | 1 | NIH | 3/25/2026 | $576 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | F31DA065413 | Site and outcomes of lynx1 allosteric modulation of α3β4-nicotinic receptors with relevance to nicotine use disorder | 000 | 1 | NIH | 2/17/2026 | $49,538 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | F31DE035006 | Functional and structural characterization of phospholipase A2 in Porphyromonas gingivalis | 001 | 1 | NIH | 5/5/2026 | $0 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | F31DE035006 | Functional and structural characterization of phospholipase A2 in Porphyromonas gingivalis | 000 | 1 | NIH | 5/5/2026 | $50,914 |
| | 2026 | 2026 | VIRGINIA COMMONWEALTH UNIVERSITY | 910 WEST FRANKLIN ST | RICHMOND | VA | 23284-9005 | RICHMOND CITY | USA | R01DA058089 | Reprogramming KZFP function to understand drug-specific transcription and behavior | 000 | 3 | NIH | 2/10/2026 | $502,202 |
|
